Biotech Values

[ghmm]

Roche’s Port Delivery System with ranibizumab shows positive phase III results in neovascular age-related macular degeneration

http://www.globenewswire.com/news-release/2020/05/27/2039063/0/en/Roche-s-Port-Delivery-System-with-ranibizumab-shows-positive-phase-III-results-in-neovascular-age-related-macular-degeneration.html

We don't know all the data so can't conclusively say but if this holds up and is reasonably safe/well tolerated why would anyone consider one of the current Wet AMD gene therapy options (ADVM and RGNX are the leading ones I'm aware of)? Both leading ones appear to need rescue injections unless you want to have significant vision loss like ADVM did with one of their cohorts to I guess make the claim no rescue injections.